Article Text

Download PDFPDF
Reactivation of IgA vasculitis following COVID-19 vaccination
  1. James A Maye1,
  2. Hsu Pheen Chong1,2,
  3. Vivek Rajagopal1,3 and
  4. William Petchey1,2
  1. 1Department of General Medicine, West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, UK
  2. 2Department of Nephrology, West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, UK
  3. 3Department of Rheumatology, West Suffolk Hospital, Bury St Edmunds, UK
  1. Correspondence to Dr James A Maye; j.anthonymaye{at}


A 23-year-old man presented to the acute assessment unit with acute-onset haematuria within 24 hours of receiving his second dose of the Pfizer-BioNTech COVID-19 vaccine. He had been diagnosed with IgA vasculitis 8 months previously. IgA vasculitis is an autoimmune condition characterised by palpable purpura affecting the lower limbs, abdominal pain, arthralgia and renal disease. He was diagnosed with an acute exacerbation of IgA vasculitis and was discharged with oral prednisolone. Reactivation or first presentation of IgA vasculitis is a rare but increasingly recognised complication of COVID-19 vaccination. This is an important new differential in the assessment of patients with haematuria following COVID-19 vaccination.

  • renal medicine
  • vasculitis
  • haematuria
  • proteinuria

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors The patient was under the care of HPC and VR. The manuscript was authored by JAM. WP and HPC contributed to editing the manuscript. The report was conceptualised and overseen by WP.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.